2017 NCCN Nursing Program: Advancing Oncology Nursing

Orlando, FL US
March 22, 2017

The NCCN 2017 Oncology Nursing Program at the NCCN 22nd Annual Conference will provide oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Information is focused on current and critical issues to provide oncology nurses with practical information that can be implemented in the practice setting. The program agenda includes the following topics: Creating a Compassionate Workplace, Strategies to Improve the Management of Febrile Neutropenia, Optimizing the Nursing Role in Difficult Conversations, Management of Dermatologic Adverse Events.  Additionally, there will be two (2) concurrent breakout sessions with simultaneous programs focusing on Clinical Updates and Issues in Colorectal Cancer, Chronic Lymphocytic Lymphoma, Bladder Cancer, and Myelofibrosis.

Target Audience

This program is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

Creating a Compassionate Workplace
• Recognize symptoms of burnout, compassion fatigue, and secondary traumatic stress in themselves or coworkers
• Outline personal strategies for self-care that can prevent the development of burnout, compassion fatigue and secondary traumatic stress
• Formulate organizational strategies for the creation of a compassionate workplace that is less conducive to burnout, compassion fatigue, and secondary traumatic stress

Strategies to Improve the Management of Febrile Neutropenia
• Detect the signs and symptoms of FN and apply factors involved in risk assessment
• Employ strategies to reduce the time to treatment of FN for patients in the emergency room
• Determine the appropriate selection of empiric antibiotics for the management of FN

Clinical Updates and Issues: Colorectal Cancer
• Evaluate the potential clinical utility of PD-1 immune checkpoint inhibitors in patients with metastatic colorectal cancer
• Summarize the most common side effects of PD-1 immune check point inhibitors
• Implement strategies for the prevention and management of treatment-related toxicities

Clinical Updates and Issues: Chronic Lymphocytic Lymphoma (CLL)
• Evaluate the treatment options for patients with newly diagnosed and relapsed or refractory CLL
• Summarize the specific complications associated with the use of small molecular inhibitors
• Implement strategies for the prevention and management of treatment-related toxicities

Clinical Updates and Issues: Bladder Cancer
• Evaluate the clinical utility of immunotherapies in patients with bladder cancer
• Summarize the adverse events associated the use of immunotherapies in bladder cancer
• Implement strategies for the prevention and management of treatment-related toxicities

Clinical Updates and Issues: Myelofibrosis
• Evaluate the treatment options for patients with myelofibrosis
• Summarize the constitutional and systemic symptoms associated with myelofibrosis
• Implement strategies for prevention and management of treatment related toxicities

Optimizing the Nursing Role in Difficult Conversations
• Describe the importance of provider-patient communication in oncology nursing
• Outline the challenges associated with difficult conversations regarding prognosis and end-of-life care
• Demonstrate tactics for approaching difficult conversations with oncology patients and their families

Management of Dermatologic Adverse Events
• Evaluate the antineoplastic therapies that may trigger adverse dermatologic events
• Identify and manage the different types of adverse dermatologic events that may occur with antineoplastic therapy
• Propose supportive care measures that may be used for patients experiencing adverse dermatologic events

Additional information
Supporters: 

Supported by educational grants from Gilead Sciences, Medical Affairs; Pfizer; and Taiho Oncology.

This activity is supported by educational funding provided by Amgen.

This activity is supported by independent educational grants from AbbVie; Incyte; and Merck Co., Inc.

Course summary
Available credit: 
  • 5.50 ANCC contact hours
  • 5.50 Participation
Course opens: 
03/20/2017
Course expires: 
08/01/2018
Event starts: 
03/22/2017 - 8:00am
Event ends: 
03/22/2017 - 3:00pm
Cost:
$0.00
Rosen Shingle Creek
9939 Universal Boulevard
Orlando, FL 32819
United States

All faculty and activity planners participating in NCCN Continuing Education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below disclose no relevant financial relationships:
Katherine Byar, MSN, APN, BC, BMTCN
Susan Childress, RN, MN, OCN
Emily Knight, RN, NP, OCN
Erika Barrett Meneely, NP
Miranda Naegele, MSN, RN, LMT, CEN

The faculty listed below disclose the following relevant financial relationships:
Kathryn Ciccolini, BSN, RN, OCN, DNC
Amgen Inc.: Consulting Fees, Honoraria Self
Roche Laboratories, Inc.: Consulting Fees, Honoraria

Anne Kolenic, MSN, RN, AOCNS
General Electric – Healthcare Division: Equity Interest/Stock Options (Spouse)

Cyndy Simonson, MS, APRN-BC, AOCN
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Bayer HealthCare: Product/Speakers Bureau
Celgene Corporation: Product/Speakers Bureau
Genentech, Inc.: Product/Speakers Bureau
Sandoz Inc.: Scientific Advisor
Taiho Parmaceuticals Co., Ltd.: Product/Speakers Bureau

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Robert W. Carlson, MD; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Kimbro, MBA, CPA; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN (Employed by NCCN until February 7, 2017); Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser (Employed by NCCN until February 3, 2017); Gary J. Weyhmuller, MBA, SPHR

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Mary Anne Bergman; Mary Dwyer, MS; Ellen Erkess Uskuraitis; Deborah Freedman-Cass, PhD; Lisa Gurski, PhD; Miranda Hughes, PhD; Rashmi Kumar, PhD; Jillian Scavone, PhD; Hema Sundar, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates this educational activity for a maximum of 5.5 contact hours.

Available Credit

  • 5.50 ANCC contact hours
  • 5.50 Participation

Accreditation Period

Course opens: 
03/20/2017
Course expires: 
08/01/2018

Price

Cost:
$0.00
Please login or register to take this course.